Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension

被引：0
|
作者：
Siegel, C. [1 ]
Danese, S. [2 ,3 ]
Rubin, D. T. [4 ]
Sabino, J. [5 ]
Long, M. D. [6 ]
Cross, R. K. [7 ]
Armuzzi, A. [8 ,9 ]
Blumenstein, I. [10 ]
Kobayashi, T. [11 ]
Lama, S. [12 ]
Charles, L. [12 ]
Cetin, V. [12 ]
Petersen, A. [12 ]
Wu, H. [12 ]
Wang, D. [13 ]
Jain, A. [12 ]
D'Haens, G. [14 ]
机构：
[1] Dartmouth Hitchcock Clin, Gastroenterol, Lebanon, NH USA
[2] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Milan, Italy
[3] Univ Vita Salute San Raffaele, Gastroenterol & Endoscopy, Milan, Italy
[4] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Inflammatory Bowel Dis, Chicago, IL USA
[5] Univ Hosp Leuven, Gastroenterol, Dept Gastroenterol, Leuven, Belgium
[6] Univ N Carolina, Chapel Hill, NC USA
[7] Univ Maryland, Sch Med, Gastroenterol & Hepatol, Baltimore, MD 21201 USA
[8] IRCCS Humanitas Res Hosp Rozzano, Inflammatory Bowel Dis, IBD Ctr, Milan, Italy
[9] Humanitas Univ Pieve Emanuele, Dept Biomed Sci, Milan, Italy
[10] Goethe Univ Hosp, Inflammatory Bowel Dis, Frankfurt, Germany
[11] Kitasato Univ, Gastroenterol, Kitasato Inst Hosp, Tokyo, Japan
[12] Bristol Myers Squibb KK, Princeton, NJ USA
[13] Bristol Myers Squibb KK, Tokyo, Japan
[14] Amsterdam Univ Med Ctr, Gastroenterol & Hepatol, Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP16
引用
收藏
页码：I100 / I101
页数：2
相关论文
共 50 条
  • [31] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, K.
    Hoogerheyde, J.
    Afsari, S.
    Sheffield, J. K.
    Shi, F.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
  • [32] Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment
    Sands, Bruce E.
    Kobayashi, Taku
    Wu, Jianmin
    Wang, Isabella Yali
    Zhu, Baojin
    Redondo, Isabel
    Peyrin-Biroulet, Laurent
    Walsh, Alissa
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1042 - S1043
  • [33] Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study (vol 18, p i1823, 2024)
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (08): : 1357 - 1357
  • [34] THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Harris, Sarah
    Wu, Chun
    Li, Yicong
    Maddux, Rachel
    Hu, Sarah
    Petersen, AnnKatrin
    GASTROENTEROLOGY, 2022, 162 (07) : S973 - S973
  • [35] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Doug
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S20 - S21
  • [36] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Douglas
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S652 - S652
  • [37] Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study
    Cross, Raymond K.
    Danese, Silvio
    Wolf, Douglas C.
    Matsuoka, Katsuyoshi
    Dotan, Iris
    Boland, Brigid S.
    Raffals, Laura E.
    Mehra, Dimpy
    Santiago, Norma Ruiz
    Petersen, AnnKatrin
    Desai, Manik
    Wu, Hsiuanlin
    Wang, Dong
    Osterman, Mark T.
    Jain, Anjali
    Lindsay, James O.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10): : S853 - S854
  • [38] Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study
    Cross, Raymond K.
    Danese, Silvio
    Wolf, Douglas C.
    Matsuoka, Katsuyoshi
    Dotan, Iris
    Boland, Brigid S.
    Raffals, Laura E.
    Mehra, Dimpy
    Santiago, Norma Ruiz
    Petersen, Annkatrin
    Desai, Manik
    Wu, Hsiuanlin
    Wang, Dong
    Osterman, Mark T.
    Jain, Anjali
    Lindsay, James O.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S853 - S854
  • [39] Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Adedokun, O. J.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    Tarabar, D.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S248 - S249
  • [40] Ozanimod in Patients with Moderate-to-Severe Ulcerative Colitis: Long-Term Safety and Efficacy from the Phase 2 TOUCHSTONE Study 4-Year Open-Label Extension
    Silvio, Danese
    Brian, Feagan
    Stephen, Hanauer
    Igor, Jovanovic
    Subrata, Ghosh
    AnnKatrin, Petersen
    Steven, Hua
    Hwan, Lee Ji
    Lorna, Charles
    Denesh, Chitkara
    William, Sandborn
    Geert, D'Haens
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S8 - S8
12345